No Data
No Data
Zhejiang Shengda Bio-pharm Co., Ltd. 2024 Semi-Annual Report
Summary of the Semi-annual Report of Zhejiang Shengda Bio-pharmaceutical Co., Ltd. in 2024.
zhejiang shengda bio-pharm (603079.SH): Plans to launch an employee stock ownership plan in 2024, raising no more than 4.9995 million yuan.
On August 22, Shengda Bio-pharm (603079.SH) announced its employee stock holding plan for 2024. The stocks for this employee stock holding plan are sourced from the company's repurchase dedicated account for repurchasing Shengda Bio-pharm A shares common stock. The target number of stocks that this employee stock holding plan intends to hold is no more than 0.8725 million shares, accounting for 0.51% of the total capital of 171.188958 million shares of the company on the date of the announcement of this employee stock holding plan draft. The sources of funds for this employee stock holding plan include legal employee compensation, self-raised capital, and other methods permitted by laws and regulations. There is no financial assistance provided by the company to shareholders or loans provided to them.
Zhejiang Shengda Bio-Pharm (603079.SH): Non-primary product vitamins D3 are fodder grade.
On July 22, Gelunhui reported that Zhejiang Shengda Bio-Pharm (603079.SH) stated on the investor interaction platform that the company's main vitamin products are biotin and folic acid. Non-main vitamin products, such as vitamin D3 (coated), are of fodder grade.
Zhejiang Shengda Bio-Pharmaceutical Co., Ltd. releases its forecast for half-yearly earnings in 2024.
Zhejiang Shengda Bio-Pharm (603079.SH): Net profit in the first half of the year is expected to reach 180 million yuan to 220 million yuan.
On July 10th, Gelonhui announced that Zhejiang Shengda Bio-pharm (603079.SH) expects to achieve a net income of 18-22 million yuan owned by the parent company in the first half of 2024, compared to the same period last year (disclosed data), it will turn losses into profits. It is expected that the net income of deducting non-recurring gains and losses belonging to the parent company in the first half of 2024 will be from 4.6 million yuan to 5.8 million yuan. The company's product sales structure has been optimized compared to the same period last year.
No Data